A genome-wide linkage scan has identified the chromosome 17p11.2-q11.2 region as the susceptibility locus for fibromyalgia.
Though the total National Institutes of Health (NIH) budget has stayed flat over the past several years, chronic pain research has enjoyed an expanded slice of the federal funding pie, as dollars committed to that portion of science grew from $279 million in 2008 to $396 million in 2012.
Results from a small study indicate patients with difficult-to-treat diabetic peripheral neuropathy (DPN) may benefit from therapy with tanezumab, a humanized monoclonal antibody against nerve growth factor.
Analysis of claims data finds patients often receive starting doses of Butrans that do not follow published recommendations, with more than one-third of patients receiving initial doses that are too low.
The current national shortfall in neurologists is about 11 percent, and is likely to increase to 19 percent by 2025.
Successful CRPS management should be viewed as a continuum that requires a flexible treatment approach that incorporates pharmacologic and nonpharmacologic components.